faricimab   Click here for help

GtoPdb Ligand ID: 11420

Synonyms: faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®
Approved drug
faricimab is an approved drug (EMA & FDA (2022))
Compound class: Antibody
Comment: Faricimab is a bispecific monoclonal antibody that simultaneously binds to angiopoietin 2 (Ang2) and vascular endothelial growth factor A (VEGF-A) [3-4]. It is an angiogenesis inhibitor. The FcRn and FcγR binding sites of faricimab have been modified to disable its Fc‐mediated effector functions. Faricimab does not bind to Ang1 [4].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
VEGFA Primary target of this compound Hs Antibody Binding 8.5 pKd - 4
⤷ pKd 8.5 (Kd 3x10-9 M) [4]
Description: Binding affinity by ITC, to VEGFA121 and VEGFA165.
angiopoietin-2 Primary target of this compound Hs Antibody Binding 7.7 pKd - 4
⤷ pKd 7.7 (Kd 2.2x10-8 M) [4]
Description: Binding affinity to a ANG-2 RBD-Fc fusion protein bt ITC